Incyte Q2 2022 Earnings Report
Key Takeaways
Incyte reported strong second-quarter results with total revenues increasing by 29% year-over-year to $911 million. The company highlighted multiple approvals and continued advancement of its pipeline, including the launch of Opzelura in atopic dermatitis and its approval for nonsegmental vitiligo.
Total revenues increased 29% year-over-year to $911 million.
Jakafi net product revenues reached $598 million, a 13% increase year-over-year.
Opzelura was approved for repigmentation of nonsegmental vitiligo and its launch in atopic dermatitis is progressing well.
Olumiant and Jakavi received multiple approvals for alopecia areata and graft-versus-host disease, respectively.
Incyte
Incyte
Incyte Revenue by Segment
Incyte Revenue by Geographic Location
Forward Guidance
Incyte is tightening its full year 2022 guidance for Jakafi net product revenues as a result of our strong second quarter performance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income